糖尿病管理中的肥胖问题及其干预

doi:10.5246/jcps.2015.06.053

摘要/Abstract

摘要：

超重和肥胖发生率的增加激起糖尿病的同步流行。因为糖尿病和超重/肥胖引起心血管疾病的发病率和死亡率增加, 它们均是心血管疾病的重要危险因素, 使得糖尿病和超重/肥胖都已经成为重要的公共卫生问题。在中国, 心血管疾病是引起死亡的首要原因。已经证实, 超重与2型糖尿病、高血压、血脂异常、代谢综合征以及某些癌症的发病率增高有关; 而减重可以明显减少肥胖相关疾病的发生。超重和肥胖是糖尿病及心血管疾病重要的、可改变的危险因素。肥胖的治疗有了令人鼓舞的进展。2013年, 美国医学会宣布肥胖是一种“疾病”, 需要一系列的医学干预以促进肥胖的治疗和预防。自从2012年起, 美国FDA批准了4种新药用于减肥治疗。

关键词: 肥胖, 2型糖尿病, 肥胖治疗, 减肥药物

Abstract:

The epidemic of diabetes has been fueled by a parallel increase in the prevalence of overweight and obesity. Both diabetes and overweight/obesity have become major public health problems causing increased morbidity and mortality and are important risk factors for cardiovascular disease.Cardiovascular disease is the leading cause of death in China. Excess weight has been shown to be associated with increased prevalence of type 2 diabetes, hypertension, dyslipidemia, metabolic syndrome and certain cancers; while weight loss dramatically reduces these obesity-related diseases. Overweight and obesity are important modifiable risk factors for diabetes and cardiovascular disease. There has also been encouraging progress in treatments for obesity. In 2013, the American Medical Association declared obesity a “disease state”requiring a range of medical interventions to advance obesity treatment and prevention. Since 2012, four new drugs have been approved by the U.S. FDA for the treatment of obesity.

Key words: Obesity, Type 2 diabetes mellitus, Obesity treatment, Anti-obesity drugs

中图分类号:

R951

Supporting:

谢晓慧, 王菲, 崔家玉. 糖尿病管理中的肥胖问题及其干预[J]. 中国药学(英文版), 2015, 24(6): 412-418.

Xiaohui Xie, Fei Wang, Jiayu Cui. The impact of obesity in managing diabetes[J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(6): 412-418.

参考文献

[1] Xu, Y.; Wang, L.; He, J.; Bi, Y.; Li, M.; Wang, T.; Wang, L.; Jiang, Y.; Dai, M.; Lu, J.; Xu, M.; Li, Y.; Hu, N.; Li, J.; Mi, S.; Chen, C.S.; Li, G.; Mu, Y.; Zhao, J.; Kong, L.; Chen, J.; Lai, S.; Wang, W.; Zhao, W.; Ning, G.; 2010 China Noncommunicable Disease Surveillance Group. JAMA. 2013, 310, 948–959.

[2] Pan, X.R.; Yang, W.Y.; Li, G.W.; Li, J. Diabetes Care. 1997, 20, 1664–1669.

[3] Yang, W.; Lu, J.; Weng, J.; Jia, W.; Ji, L.; Xiao, J.; Shan, Z.; Liu, J.; Tian, H.; Ji, Q.; Zhu, D.; Ge, J.; Lin, L.; Chen, L.; Guo, X.; Zhao, Z.; Li, Q.; Zhou, Z.; Shan, G.; He, J. N. Engl. J. Med. 2010, 362, 1090–1101.

[4] Hu, F.B. Diabetes Care. 2011, 34, 1249–1257.

[5] Yang, X.G.; Zhai, F.Y.; Piao, J.H.; Zhao, W.H.; He, Y.N.; Zhang, J. Chin. Prev. Med. 2010, 11, 5–7.

[6] Cui, Z.; Huxley, R.; Wu, Y.; Dibley, M.J. Int. J. Pediatr. Obes. 2010, 5, 365–374.

[7] Xi, B.; Liu, F.; Hao, Y.; Dong, H.; Mi, J. Int. J. Cardiol. 2014, http:dx.doi.org/10.1016.j.ijcard.2014.04.098

[8] Chan, J.C.; Zhang, Y.; Ning, G. Lancet Diabetes Endocrinol. 2014, http://dx.doi.org/10.1016/S2213–8587(14)70144–5

[9] Wang, H.; Zhai, F. Obes. Rev. 2013, 14, 134–140.

[10] AMA adopts new policies 2013. Available at http://www.ama–assn.org/ama/pub/news/news/2013/2013-06-18-new-ama-policies-annual-meeting.page. Accessed 11-23-14

[11] Jensen, M.D.; Ryan, D.H.; Apovian, C.M.; Ard, J.D.; Comuzzie, A.G.; Donato, K.A.; Hu, F.B.; Hubbard, V.S.; Jakicic, J.M.; Kushner, R.F.; Loria, C.M.; Millen, B.E.; Nonas, C.A.; Pi-Sunyer, F.X.; Stevens, J.; Stevens, V.J.; Wadden, T.A.; Wolfe, B.M.; Yanovski, S.Z.; Jordan, H.S.; Kendall, K.A.; Lux, L.J.; Mentor-Marcel, R.; Morgan, L.C.; Trisolini, M.G.; Wnek, J.; Anderson, J.L.; Halperin, J.L.; Albert, N.M.; Bozkurt, B.; Brindis, R.G.; Curtis, L.H.; DeMets, D.; Hochman, J.S.; Kovacs, R.J.; Ohman, E.M.; Pressler, S.J.; Sellke, F.W.; Shen, W.K.; Smith, S.C.Jr.; Tomaselli, G.F.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. Circulation. 2014, 129, S102–S138.

[12] National Institutes of Health. Obes. Res. 1998, 6, 51S–209S.

[13] American Diabetes Association. Standards of Medical Care in Diabetes-2015. Diabetes Care. 2015, 38, S1–S96.

[14] Li, S.; Xiao, J.; Ji, L.; Weng, J.; Jia, W.; Lu, J.; Zhou, Z.; Guo, X.; Liu, J.; Shan, Z.; Zhu, D.; Chen, L.; Zhao, Z.; Tian, H.; Ji, Q.; Ge, J.; Li, Q.; Lin, L.; Yang, Z.; He, J.; Yang, W. J. Diabetes Complications. , 28, 470–476.2014

[15] Katz, E.G.; Stevens, J.; Truesdale, K.P.; Cai, J.; North, K.E.; Steffen, L.M. Asia Pac. J. Clin. Nutr. 2013, 22, 626–634.

[16] Cornier, M.A.; Dabelea, D.; Hernandez, T.L.; Lindstrom, R.C.; Steig, A.J.; Stob, N.R.; Van Pelt, R.E.; Wang, H.; Eckel, R.H. Endocr. Rev. 2008, 29, 777–822.

[17] Zhou, B.F. Biomed Environ. Sci. 2002, 15, 83–96.

[18] Stern, D.; Smith, L.P.; Zhang, B.; Gordon-Larsen, P.; Popkin, B.M. Int. J. Obes. 2014. doi: 10.1038/ijo.2014.74.

[19] Li, G.; Chen, X.; Jang, Y.; Wang, J.; Xing, X.; Yang, W.; Hu, Y. Obes. Rev. 2002, 3, 167–172.

[20] Pan, X.R.; Li, G.W.; Hu, Y.H.; Wang, J.X.; Yang, W.Y.; An, Z.X.; Hu, Z.X.; Lin, J.; Xiao, J.Z.; Cao, H.B.; Liu, P.A.; Jiang, X.G.; Jiang, Y.Y.; Wang, J.P.; Zheng, H.; Zhang, H.; Bennett, P.H.; Howard, B.V. Diabetes Care. 1997, 20, 537–544.

[21] Knowler, W.C.; Barrett-Connor, E.; Fowler, S.E.; Hamman, R.F.; Lachin, J.M.; Walker, E.A.; Nathan, D.M.; Diabetes Prevention Program Research Group. N. Engl. J. Med. 2002, 346, 393–403.

[22] Tuomilehto, J.; Lindström, J.; Eriksson, J.G.; Valle, T.T.; Hämäläinen, H.; Ilanne-Parikka, P.; Keinänen-Kiukaanniemi, S.; Laakso, M.; Louheranta, A.; Rastas, M.; Salminen, V.; Uusitupa, M.; Finnish Diabetes Prevention Study Group. N. Engl. J. Med. 2001, 344, 1343–1350.

[23] Li, G.; Zhang, P.; Wang, J.; Gregg, E.W.; Yang, W.; Gong, Q.; Li, H.; Li, H.; Jiang, Y.; An, Y.; Shuai, Y.; Zhang, B.; Zhang, J.; Thompson, T.J.; Gerzoff, R.B.; Roglic, G.; Hu, Y.; Bennett, P.H. Lancet. 2008, 371, 1783–1789.

[24] Lindström, J.; Ilanne-Parikka, P.; Peltonen, M.; Aunola, S.; Eriksson, J.G.; Hemiö, K.; Hämäläinen, H.; Härkönen, P.; Keinänen-Kiukaanniemi, S.; Laakso, M.; Louheranta, A.; Mannelin, M.; Paturi, M.; Sundvall, J.; Valle, T.T.; Uusitupa, M.; Tuomilehto, J.; Finnish Diabetes Prevention Study Group. Lancet. 2006, 368, 1673–1679.

[25] Diabetes Prevention Program Research Group; Knowler, W.C.; Fowler, S.E.; Hamman, R.F.; Christophi, C.A.; Hoffman, H.J.; Brenneman, A.T.; Brown-Friday, J.O.; Goldberg, R; Venditti, E; Nathan, D.M. Lancet. 2009, 374, 1677–1686.

[26] Chiasson, J.L.; Josse, R.G.; Gomis, R.; Hanefeld, M.; Karasik, A.; Laakso, M.; STOP-NIDDM Trail Research Group. Lancet. 2002, 359, 2072–2077.

[27] DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein, H.C.; Yusuf, S.; Bosch, J.; Pogue, J.; Sheridan, P.; Dinccag, N.; Hanefeld, M.; Hoogwerf, B.; Laakso, M.; Mohan, V.; Shaw, J.; Zinman, B.; Holman, R.R. Lancet. 2006, 368, 1096–1105.

[28] Diabetes Prevention Program Research Group. Diabetes Care. 2012, 35, 723–730.

[29] Wing, R.R.; Look AHEAD Research Group. Diabetes Obes. Metab. 2014, 16, 1183–1191.

[30] Yanovski, S.Z.; Yanovski, J.A. JAMA. 2014, 311, 74–86.

[31] Connolly, H.M.; Crary, J.L.; McGoon, M.D.; Hensrud, D.D.; Edwards, B.S.; Edwards, W.D.; Schaff, H.V. N. Engl. J. Med. 1997, 337, 581–588.

[32] James, W.P.; Caterson, I.D.; Coutinho, W.; Finer, N.; Van Gaal, L.F.; Maggioni, A.P.; Torp-Pedersen, C.; Sharma, A.M.; Shepherd, G.M.; Rode, R.A.; Renz, C.L. N. Engl. J. Med. 2010, 363, 905–917.

[33] Norris, S.L.; Zhang, X.; Avenell, A.; Gregg, E.; Schmid, C.H.; Lau, J. Cochrane Database Syst. Rev. 2005, 1, CD004096.

[34] Smith, S.R.; Weissman, N.J.; Anderson, C.M.; Sanchez, M.; Chuang, E.; Stubbe, S.; Bays, H.; Shanahan, W.R. N. Engl. J. Med. 2010, 363, 245–256.

[35] Fidler, M.C.; Sanchez, M.; Raether, B.; Weissman, N.J.; Smith, S.R.; Shanahan, W.R.; Anderson, C.M. J. Clin. Endocrinol. Metab. 2011, 96, 3067–3077.

[36] O’Neil, P.M.; Smith, S.R.; Weissman, N.J.; Fidler, M.C.; Sanchez, M.; Zhang, J.; Raether, B.; Anderson, C.M.; Shanahan, W.R. Obesity (Silver Spring). 2012, 20, 1426–1436.

[37] Allison, D.B.; Gadde, K.M.; Garvey, W.T.; Peterson, C.A.; Schwiers, M.L.; Najarian, T.; Tam, P.Y.; Troupin, B.; Day, W.W. Obesity (Silver Spring). 2012, 20, 330–342.

[38] Gadde, K.M.; Allison, D.B.; Ryan, D.H.; Peterson, C.A.; Troupin, B.; Schwiers, M.L.; Day, W.W. Lancet. 2011, 377, 1341–1352.

[39] FDA approves weight-management drug Contrave. http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm413896.htm . Accessed 11-23-14.

[40] FDA approves weight-management drug Saxenda. http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm427913.htm. Accessed 12-29-2014.

[41] Schauer, P.R.; Kashyap, S.R.; Wolski, K.; Brethauer, S.A.; Kirwan, J.P.; Pothier, C.E.; Thomas, S.; Abood, B.; Nissen, S.E.; Bhatt, D.L. N. Engl. J. Med. 2012, 366, 1567–1576.

[42] Sjöström, L.; Narbro, K.; Sjöström, C.D.; Karason, K.; Larsson, B.; Wedel, H.; Lystig, T.; Sullivan, M.; Bouchard, C.; Carlsson, B.; Bengtsson, C.; Dahlgren, S.; Gummesson, A.; Jacobson, P.; Karlsson, J.; Lindroos, A.K.; Lönroth, H.; Näslund, I.; Olbers, T.; Stenlöf, K.; Torgerson, J.; Agren, G.; Carlsson, L.M. N. Engl. J. Med. 2007, 357, 741-752.

[43] Adams, T.D.; Gress, R.E.; Smith, S.C.; Halverson, R.C.; Simper, S.C.; Rosamond, W.D.; Lamonte, M.J.; Stroup, A.M.; Hunt, S.C. N. Engl. J. Med. 2007, 357, 753-761.